Real-world clinical outcomes of biologic-naive non-complicated Crohn's disease patients treated with vedolizumab: Results from the EVOLVE study

被引：0
|
作者：
Yarur, A. [1 ]
Mantzaris, G. J. [2 ]
Kopylov, U. [3 ]
Bassel, M. [4 ]
Brett, N. [4 ]
Kim, H. [5 ]
Lopez, C. [6 ]
Saha, S. [7 ]
Kifnidi, C. [8 ]
Agboton, C. [9 ]
Adsul, S. [9 ]
Demuth, D. [10 ]
Luo, M. [11 ]
Wang, S. [11 ]
Bressler, B. [12 ]
机构：
[1] Med Coll Wisconsin, Gastroenterol, Milwaukee, WI 53226 USA
[2] Evangelismos Med Ctr, Gastroenterol, Athens, Greece
[3] Sheba Med Ctr, Gastroenterol, Tel Aviv, Israel
[4] Evidera, Real World Evidence, Montreal, PQ, Canada
[5] Evidera, Data Analyt, Waltham, MA USA
[6] Takeda Pharmaceut USA Inc, Med Affairs, Deerfield, IL USA
[7] Takeda Canada Inc, Med Affairs, Oakville, ON, Canada
[8] Takeda Hellas SA, Med Affairs, Athens, Greece
[9] Takeda Pharmaceut Int AG, Global Med Affairs, Zurich, Switzerland
[10] Takeda Pharmaceut Int, Evidence Generat & Publicat, Singapore, Singapore
[11] Takeda Pharmaceut Int, Global Outcomes Res, Boston, MA USA
[12] St Pauls Hosp, Gastroenterol, Vancouver, BC, Canada
来源：
JOURNAL OF CROHNS & COLITIS | 2020年 / 14卷
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
P387
引用
收藏
页码：S360 / S361
页数：2
相关论文
共 50 条
  • [31] REAL-WORLD EFFECTIVENESS OF FIRST-LINE BIOLOGIC VEDOLIZUMAB IN CROHN'S DISEASE: ANALYSIS OF HIGHER TREATMENT EFFECT SUBPOPULATION FROM THE EVOLVE STUDY
    Yarur, Andres
    Bressler, Brian
    Wang, Song
    Adsul, Shashi
    Kamble, Pravin
    Luo, Michelle
    Cook, Erin
    Sajeev, Gautam
    Dieye, Ibou
    Mantzaris, Gerassimos J.
    GASTROENTEROLOGY, 2021, 160 (06) : S4 - S4
  • [32] PATIENTS WITH CROHN'S DISEASE TREATED WITH USTEKINUMAB VERSUS VEDOLIZUMAB IN REAL-WORLD SETTINGS
    Chiorean, Michael V.
    Jiang, Jeanne
    Candela, Ninfa
    Chen, Grace
    Romdhani, Hela
    Latremouille-Viau, Dominick
    Shi, Sherry
    Bungay, Rebecca
    Fan, Tao
    GASTROENTEROLOGY, 2020, 158 (06) : S407 - S408
  • [33] Clinical Effectiveness and Safety of Vedolizumab vs. Infliximab in Biologic-Naive Ulcerative Colitis Patients: A Brazilian Real-World Multicentric Observational Study
    Ferreira, S.
    Chebli, J. M. F.
    Parra, R.
    Sassaki, L. Yukie
    de Mello, M. K.
    Luporini, R. L.
    Chebli, L. A.
    Nobrega, F. J. Firmino
    da Silva, B. C.
    Dutra, R. D. M.
    Vasconcelos, J. R. de Oliveira
    Sales, M. P. Moraes
    Feres, O.
    Parente, J. M. L.
    Troncon, L. E. D. A.
    JOURNAL OF CROHNS & COLITIS, 2024, 18 : I1087 - I1088
  • [34] Clinical Effectiveness and Safety of Vedolizumab in Patients With Crohn's Disease in China: Results From a Real World Study
    Kang, Chao
    Jie, Zhong
    Xie, Li
    Hu, Yaqiu
    Gianchetti, Lauren
    Khan, Zaeem
    Farhat, Zeinab
    Kamble, Pravin
    Xiang, Gao
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2024, 119 (10S): : S813 - S814
  • [35] Clinical characteristics of patients with Crohn's disease or ulcerative colitis treated with vedolizumab: a real-world data analysis
    Liang, H.
    Manne, S.
    Shick, J.
    Yu, S.
    Fusco, G.
    Dolin, P.
    JOURNAL OF CROHNS & COLITIS, 2016, 10 : S466 - S467
  • [36] Clinical Characteristics of Patients With Crohn's Disease or Ulcerative Colitis Treated With Vedolizumab - A Real-World Data Analysis
    Liang, Huifang
    Manne, Sudhakar
    Shick, Jesse
    Yu, Shawn
    Fusco, Gregory
    Dolin, Paul
    GASTROENTEROLOGY, 2016, 150 (04) : S789 - S789
  • [37] Real-World Effectiveness of Vedolizumab vs Anti-TNF in Biologic-naive Crohn's Disease Patients: A 2-year Propensity-score-adjusted Analysis from the VEDOIBD-Study
    Bokemeyer, Bernd
    Plachta-Danielzik, Sandra
    di Giuseppe, Romina
    Efken, Philipp
    Mohl, Wolfgang
    Hoffstadt, Martin
    Krause, Thomas
    Schweitzer, Axel
    Schnoy, Elisabeth
    Atreya, Raja
    Teich, Niels
    Trentmann, Leo
    Ehehalt, Robert
    Hartmann, Petra
    Schreiber, Stefan
    INFLAMMATORY BOWEL DISEASES, 2024, 30 (05) : 746 - 756
  • [38] Dose escalation of biologics in biologic-naive patients with Crohn's disease: Outcomes from the ODESSA-CD study
    Cleveland, Noa Krugliak
    Ghosh, Sabyasachi
    Kathe, Niranjan
    Umashankar, Kandavadivu
    Mirchandani, Kirti
    Hait, Arunima
    Paul, Riyanka
    Candela, Ninfa
    Fan, Tao
    Rubin, David T.
    JOURNAL OF MANAGED CARE & SPECIALTY PHARMACY, 2024, 30 (11): : 1276 - 1287
  • [39] Patients with Crohn's disease treated with ustekinumab vs. vedolizumab in real-world settings
    Chiorean, M.
    Jiang, J.
    Candela, N.
    Chen, G.
    Romdhani, H.
    Latremouille-Viau, D.
    Shi, S.
    Bungay, R.
    Fan, T.
    JOURNAL OF CROHNS & COLITIS, 2020, 14 : S630 - S630
  • [40] Real-World Clinical Effectiveness and Safety of Vedolizumab and Ustekinumab in Bio-Na<spacing diaeresis>ive Patients With Complex Crohn's Disease: Results From the EVOLVE Expansion Study
    Ferrante, Marc
    Christensen, Britt
    Bressler, Brian
    Khan, Zaeem
    Bassel, Marielle
    Kamble, Pravin
    Adsul, Shashi
    Farhat, Zeinab
    Scharl, Michael
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2023, 118 (10): : S627 - S628
12345